The euphoric sentiment of October and early November has long since evaporated. The early December drop in the crypto market saw the price of Solana drop below the $200 mark, and since then the price established a shift in market structure to bearish. Repeated waves of selling have brought Solana prices to $90 at the […]

Swing, a blockchain startup that enables cross-chain liquidity and liquidity aggregation across blockchains, announced that it has raised USD 6 Million in a strategic funding round from leading investors in the blockchain ecosystem. Housing several trading, lending, and borrowing protocols, the Ethereum ecosystem dominates the decentralized financial (DeFi) area. This has reverberated across the network, pushing Ethereum to its limits but also speeding up the pace of invention and experimentation. Swing leverages layer 1 and layer 2 solutions like Polygon, Binance Smart Chain, Avalanche, Solana, Arbitrum, and more to get past and challenge Ethereum’s performance restrictions. The strategic round of funding was led by Republic Capital and also saw participation from blockchain-centric VCs including Avalanche Labs, Bitcoin.com, Skynet EGLD Capital, Celer, Ascensive Assets, Haskey, Morningstar Ventures, Kane & Rao among others. With this round of strategic funding, Swing has achieved a valuation of USD 60 Million, making it one of the most sought-after projects in the DeFi space. With this successful fundraiser, Swing aims to fastrack its plans to launch APIs to aggregate major liquidity sources and bridges with the aim of enabling cross-chain liquidity and progress closer to its vision of decentralized liquidity across the DeFi multi-chain ecosystem. The funding will be utilized to propel Swing’s development and expansion of teams. The Future of DeFi: A Big Stride Towards Cross-Chain Infrastructure For The Internet The total value locked (TVL) in the DeFi space, a measure of the number of assets staked in a specific protocol, quadrupled in 2021 alone bringing its TVL to USD 201.55 Billion in 2022. The DeFi space has witnessed a boom of decentralized exchanges (DEXs) and protocols, the issue of sporadic liquidity is ever persistent. Further, DEX Aggregators find themselves restrained to connecting liquidity pools on the Ethereum chain thereby, limiting possibilities of multi-chain liquidity aggregation. While Ethereum is one of the most prominent chains for building protocols, it is no revelation that its network congestion and stark lack of scalability have resulted in high latency and soaring gas fees. It is vividly clear that blockchain interoperability is the need of the hour to resolve the issue of liquidity fragmentation on DEXs. This is why Swing is building an efficient cross-chain infrastructure for the internet which will compose and aggregate liquidity across blockchains and thereby, move assets across multiple ecosystems with minimum slippage. This is said to become an indispensable part of the DeFi ecosystem. By enabling cross-chain transactions, the project aims to bring in a new era of decentralized trading. With these features and offerings, Swing aims to be the Stripe for cross-chain transactions. Much like how Stripe enables websites and apps to take payments over their websites, Swing will simplify cross-chain swaps and transfers for developers and businesses with its much-awaited API product. By enabling cross-chain transactions, the project aims to bring in a new era of decentralized trading. By offering a cross-chain asset exchange and decentralized liquidity protocol that uses Layer 2 chains and major EVM networks, DeFi traders, investors & developers can use Swing to move crypto capital efficiently across blockchains. AMM dexes, yield farms, lending/borrowing and staking protocols will greatly benefit from Swing’s cross-chain bridging solution. Swing navigates across top protocols and exchanges on Layer 1 and 2 chains with its cross-chain bridges and intelligent algorithms to beat and match market swap prices. Swing is currently compatible with Ethereum, Polygon, Binance Smart Chain, Harmony, Avalanche, xDai, Moonriver, and Phantom and is said to expand to Solana, Harmony, Polkadot, Cardano, Optimism, and Near soon. Concluding Thoughts The coexistence and interoperability of multiple blockchains is a necessity for the continued growth and survival of the DeFi industry. In this light, the search for an efficient and simple cross-chain trading and liquidity aggregator is more important than ever. This is where Swing’s offering to go the last mile for crypto liquidity has become a critical part of the whole crypto infrastructure. Swing will be a one-of-a-kind gamechanger to empower developers, investors, and users all over the world to move crypto assets effortlessly using blockchain smart contracts, relayers, and cross-chain bridges. The future is multi-chain! Think multichain, Think Swing!  

Zenith: The Last City is a cross-platform MMORPG available now for VR platforms including Oculus Quest, PC VR and PSVR! Check out our short guide to Zenith so you can get battle-ready and on the path to max level! #ad

Bengaluru, India, Jan 28, 2022 - (ACN Newswire) - Pixis (formerly known as Pyxis One), a leading provider of contextual codeless AI infrastructure for complete marketing optimization, today appointed Neel Pandya as the Chief Executive Officer of its operations in Europe, in addition to his responsibilities of leading the APAC business.

Neel joined Pixis in its Bengaluru office in July 2021 as the CEO of APAC, bringing immense change and progress to the way Pixis operates, and greatly streamlining expansions in the APAC region. Under his leadership, Pixis witnessed a 185% growth in revenue in the APAC region, with India independently recording a 150% of growth. Over the last 7 months, in addition to greatly stabilizing customer churn Neel has also been instrumental in adding close to 30 new enterprise customers. He also continues to play a crucial role in building a global team of collaborators in Pixis. The company which recently closed $100M in Series C funding has almost tripled in size and plans to continue rapidly hiring talent, in India and outside, as it expands into Europe.

Speaking about the new appointment, co-founder & Global CEO, Shubham A. Mishra says, "Neel has been doing a remarkable job navigating and growing the business in APAC and it gives me immense pleasure to announce Neel's appointment as CEO of our Europe business, as well. In addition to the new volley of customers we're signing up, we're also seeing record retention rates with our existing customers." Mishra continued, "Over the last few months, we've been noticing steadily increasing traction in Europe, and I believe we have the right person in Neel to lead our Europe business."

As CEO of Pixis' Europe business, Neel's key responsibilities will include leveraging existing traction in the region to profoundly grow the business and brand. Weighing in on his appointment, Venkatesh Peddi, Partner at Chiratae Ventures added, "Neel's success in the APAC region is testament to his belief in the Pixis vision, as well as his charisma as a leader. His prior experience with the European markets will serve him excellently in executing and staying on top of the expansion roadmap."

Neel is a seasoned leader who possesses impressive global experience and a deep understanding of consumers in APAC and Europe. Prior to Pixis, Neel exemplified vast professional capabilities at L'Oreal, Vodafone and GroupM. Additionally, he was named one among India's Top 40 under 40 Most Disruptive Minds, two years consecutively, and has also served as the youngest media head of all times at L'Oreal and Vodafone.

Neel Pandya, speaking about his new role, said, "The past 7 months at Pixis have seen my learning curve grow steeply, and I'm beyond honoured at being given the responsibility to grow the Europe business now. The continent is currently undergoing an interesting and exciting phase in marketing. In fact, digital advertising spends alone have amounted to over 69.4 billion Euros, making it the second biggest market after the US. I'm thoroughly looking forward to building strong teams that can support us in growing our European operations."

Pixis' recent Series C round of $100M was led by SoftBank Vision Fund 2 with participation from new investor General Atlantic. Existing investors Premji Invest, Celesta Capital and Chiratae Ventures also participated in the round. With a total of $124M raised so far, the company is all set to accelerate growth and expansions across Europe. ​​

About Pixis

Pixis is a California-based technology company that provides codeless AI infrastructure to enable customers to scale accurate data-driven marketing. The company's codeless AI infrastructure currently comprises over four-dozen proprietary AI models that are deployed across an ecosystem of products and plugins. Pixis is on a mission to provide marketers with robust plug-and-play AI products without them having to write a single line of code.

Related link
https://www.linkedin.com/posts/softbank-investment-advisers_marketing-is-one-of-the-largest-spend-categories-activity-6889927122006106112-_7xh
https://techcrunch.com/2022/01/18/softbank-ai-infrastructure-pyxis-one-pixis/

Media contacts
Brand: Pixis
Contact: Anjali Devaiah, Rishabh Chauhan
Email: [email protected] , [email protected]
Website: https://pixis.ai/

SOURCE: Pixis

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

TOKYO, Jan 28, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022. CEO Naito represented pharmaceutical companies and highlighted the achievements of NTDs elimination activities by the industry and successes achieved by multi-sectoral partnerships. He also expressed Eisai's continued support for the elimination of NTDs towards the achievement of NTD road map 2021-2030 launched by the World Health Organization (WHO) last year. The 10th anniversary event aimed to recognize a decade of progress since the London Declaration, to confirm the strong commitment of stakeholders to continue the efforts for NTDs, and to strengthen endorsements from stakeholders to the Kigali Declaration on NTDs, the successor of the London Declaration which will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda.

Tremendous achievements have been made through public-private partnership since the launch of the London Declaration to 2020. The pharma industry has contributed to the elimination of NTDs via supply of medicines which resulted in donation of 13 billion high-quality treatments. Forty-three countries have eliminated at least one NTD and 600 million people no longer require interventions against NTDs. Despite such progress, more than 1.7 billion people remain threatened by NTDs.

In the event, CEO Haruo Naito said, "Our initiatives toward NTDs elimination are rooted in the pharmaceutical company's fundamental mission to deliver medicines to those who need them to treat illness and save lives. While R&D for NTDs treatments have become more active after the London Declaration, establishment of agile and flexible regulatory approval system as well as expansion of funding which leverages public-private partnership will be required to accelerate further innovations. Utilization of digital technologies such as remote medicine will help ensure delivery of and access to healthcare service under the vulnerable social infrastructure."

Under the London Declaration, Eisai has been manufacturing and supplying diethylcarbamazine (DEC) tablets, one of the lymphatic filariasis (LF) treatments, free of charge to the WHO for the elimination of LF. To date, 2.05 billion DEC tablets manufactured at Eisai's Vizag Plant in India have been supplied to 29 countries (as of January 2022). Although LF has been eliminated in 17 countries and the number of infected people has declined by 74% since 2000, 860 million people worldwide are still exposed to the risk of infection. Eisai is committed to providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries. In addition to the supply of DEC tablets, Eisai is working on various initiatives such as support for the mass drug administrations (MDA), disease awareness and improvements in sanitation.

Furthermore, Eisai is proactively engaged in development of new treatments for NTDs through partnerships with global research organizations. Utilizing the funding from the Global Health Innovative Technology Fund (GHIT Fund) and others, Eisai is conducting joint development of new treatments such as a new treatment for LF in collaboration with the Liverpool School of Tropical Medicine and the University of Liverpool as well as treatments for mycetoma and leishmaniasis in collaboration with the Drugs for Neglected Diseases initiative (DNDi).

Eisai commits to the Kigali Declaration and strengthens collaborations with global partners to tackle NTDs towards the achievement of NTD road map 2021-2030.

Based on human health care (hhc) philosophy, Eisai seeks to contribute to the health and welfare of people in developing and emerging countries. Once they recover their health, they can resume productive activities, which will in turn contribute to economic development and expansion of the middle-income class. Eisai considers this to be a long-term investment in creating the markets for the future. Eisai is actively engaged in leveraging partnerships with governments, international organizations, academia, and non-profit private sector organizations to accelerate the development of new treatments for infectious diseases including NTDs and facilitate initiatives to improve access to medicine such as support for MDAs and disease awareness activities. Through these initiatives, Eisai seeks to further contribute to patients and their families worldwide and increase the benefits that health care provides.

About Neglected Tropic Diseases (NTDs)

Neglected Tropic Diseases (NTDs) include 20 diseases that the WHO identifies as tropical diseases which human race must overcome. More than 1.7 billion people living in the poorest and most marginalized communities worldwide are exposed to the risk of NTDs infection. The spread of NTDs is mainly caused by poor hygienic conditions associated with poverty. Infections from these diseases may result in serious physical impairment and this often results in normal economic and social activities becoming highly challenging to the individual. In the worst cases, NTDs may also result in death. The prevalence of NTDs is a stumbling block to economic growth for developing and emerging countries and represents a serious issue for these regions.
The following 20 NTDs have been designated by WHO for control or elimination: dengue and chikungunya, rabies, trachoma, buruli ulcer, yaws (endemic treponematoses], leprosy (Hansen's disease], Chagas disease, human African trypanosomiasis (sleeping sickness], leishmaniasis, taeniasis / cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, food-borne trematodiases, lymphatic filariasis, onchocerciasis (river blindness], schistosomiasis, soil-transmitted helminthiases, mycetoma, scabies and other ectoparasites, and snakebite envenoming.

About London Declaration on Neglected Tropical Diseases

On January 30, 2012, the CEOs of 13 pharmaceutical companies*, the Bill & Melinda Gates Foundation, WHO, the U.S. Agency for International Development (USAID), the U.K. Department for International Development (DFID), the World Bank, and officials from NTD-endemic countries gathered in London to pledge their support for a coordinated effort to combat 10 NTDs**. The London Declaration represents the largest international public-private partnership in the field of global health to date, and unlike past approaches undertaken by an individual organization or for a single disease, the group has committed itself to working collaboratively in an effort to comprehensively tackle issues pertaining to drug supply, distribution, development, and implementation programs as it seeks to more effectively combat NTDs.

Commemorating the London Declaration, January 30 has been designated as the World NTD Day since 2020 and campaigns are held worldwide to light up the iconic landmarks and monuments in orange and purple, the symbol colors of NTDs. Eisai is sponsoring the light up of Tokyo Tower to raise disease awareness and disseminate the importance of eliminating NTDs.

* Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, GlaxonSmithKline, Gilead, Johnson & Johnson, Merck (Merck KGaA: Germany), Merck Sharp & Dhome, Novartis, Pfizer, Sanofi
** Guinea worm disease, lymphatic filariasis, blinding trachoma, sleeping sickness (human African trypanosomiasis], leprosy, soil-transmitted helminthes, schistosomiasis, river blindness, Chagas disease, and visceral leishmaniasis

About Kigali Declaration on Neglected Tropical Diseases

As the successor of the London Declaration on NTDs launched in 2012, the Kigali Declaration represents a collective commitment from stakeholders to fight against NTDs. With the endorsements from stakeholders being initiated at the online event entitled "100% COMMITTED to End NTDs", a campaign to commemorate the 10th year anniversary of the London Declaration held on January 27, 2022, the Kigali Declaration will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda. To achieve the WHO's NTD roadmap 2021-2030, the Kigali Declaration aims to tackle NTDs comprehensively and sustainably by sustaining a multisectoral and multidisciplinary approach through public-private partnership, strengthening country ownership including establishment of local health system and domestic financing, accelerating research and development of treatments and diagnostics for NTDs and ensuring equitable access to these NTDs related products and services.

About Lymphatic Filariasis

Lymphatic filariasis (LF) is an NTD transmitted to humans via carrier mosquitoes. LF causes lymphatic dysfunction and can lead to the swelling of body parts such as legs, and cause severe pain, permanent disability and social stigma associated with disfiguring visible manifestations. As a result, patients suffer mental, social and financial losses. It is estimated that 860 million people worldwide, mainly those in developing countries, are exposed to the risk of LF. Elimination of LF is possible by stopping the spread of the infection through MDAs of three types of LF treatments including DEC tablets.

About Eisai's Commitment to Improving Global Access to Medicines including LF Elimination Program

In line with its hhc philosophy, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.

In November 2010, Eisai agreed to supply a total of 2.2 billion DEC tablets to the WHO free of charge by 2020, as there was a global shortage of high-quality DEC tablets for use in MDAs. In 2012, Eisai became the only Japanese company to participate in the London Declaration, a coordinated effort to eliminate 10 NTDs and the largest public-private partnership of its kind in the field of global health. At the London Declaration's fifth anniversary event held in April 2017, Eisai announced its plan to supply DEC tablets continuously beyond 2020, until LF is eliminated in all endemic countries where DEC tablets are needed.

Eisai has supplied 2.05 billion tablets to 29 countries through the WHO's elimination program (as of January 2022). Furthermore, in order to support the smooth implementation of the WHO's MDA programs, Eisai is engaging in initiatives to raise public awareness of LF in endemic countries. Staff members of Eisai Group cooperate with the relevant representatives in endemic countries to eliminate LF as early as possible.

In addition to the above-mentioned initiatives, Eisai is moving ahead with new drug development projects targeting malaria and NTDs such as mycetoma and LF, based on partnerships with international non-profit organizations such as the Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV), as well as research organizations such as Liverpool School of Tropical Medicine, University of Kentucky, and the Broad Institute (please refer to the table above).

Furthermore, Eisai co-established the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public-private partnership to advance development of new health technologies for the developing world, is a member of the World Intellectual Property Organization (WIPO) Re:Search Consortium, an international joint enterprise for the development of treatments for NTDs, malaria and tuberculosis led by WIPO, is a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, and is participating in the Access Accelerated initiative to promote prevention and treatment of non-communicable diseases.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022.

Oil WTI crude prices reversed earlier gains as the dollar surged following better-than-expected economic data that supported the idea that the economy can handle rapid Fed rate hikes. No one is questioning how tight the oil market remains, but there is some exhaustion after making fresh seven-year highs and that has led to some profit-taking. […]

Making its Finovate debut nearly seven years ago (as 3E Software), Teslar Software has become a valued strategic partner for community financial institutions across the United States. The firm’s portfolio management solutions aggregate and automate both lending and deposit operations into a single system, enabling them to scale and enhance processes throughout the institution. Just Read more...

The post Lending, Automation, and Digital Transformation with Teslar Software’s Amy Berger appeared first on Finovate.

Zenith might be a more traditional take on the VR MMO than you're expecting, but it's got some great ideas and foundations to help it go the distance. Here's the beginnings of our review, with more to come!

Wanderer is a hugely ambitious VR game that somehow achieves almost everything it sets out to accomplish. Our full review is here.

The post ‘Wanderer’ Review – A Time Traveling Delight That’s Just Shy of Greatness appeared first on Road to VR.

As the NFT and Metaverse gaming space continues to make leaps and bounds in 2022, we are slowly witnessing the evolution of the gaming space – not only in terms of story, character and gameplay, but also the underlying economies which form the financial foundations of a given project.  One example of this is Wizardia. […]